(EVAX) Price Target Increased by 414.29% to 18.36

The average one-year price target for Evaxion Biotech A (NasdaqCM:EVAX) has been revised to 18.36 / share. This is an increase of 414.29% from the prior estimate of 3.57 dated January 16, 2024.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 14.14 to a high of 21.00 / share. The average price target represents an increase of 392.23% from the latest reported closing price of 3.73 / share.